Keywords:
Lipoproteins, atherosclerosis, lipoprotein (a), kringles, siRNA, anti-sense oligonucleotide, immunoassay, oxidized phospholipids.
[30]
O'Donoghue ML, López JA, Knusel B, et al. Study design and rationale for the OCEAN(a)-DOSE (olpasiran trials of cardiovascular events and LipoproteiN(a) reduction-DOSE finding study)trial. American Heart J 2022.